PDF(Pubmed)
Abstract：
BACKGROUND: This study was designed to examine the effect of resveratrol on mitochondrial biogenesis, oxidative stress (OS), and assisted reproductive technology (ART) outcomes in individuals with polycystic ovary syndrome (PCOS).
METHODS: Fifty-six patients with PCOS were randomly assigned to receive 800 mg/day of resveratrol or placebo for 60 days. The primary outcome was OS in follicular fluid (FF). The secondary outcome involved assessing gene and protein expression related to mitochondrial biogenesis, mitochondrial DNA (mtDNA) copy number, and adenosine triphosphate (ATP) content in granulosa cells (GCs). ART outcomes were evaluated at the end of the trial.
RESULTS: Resveratrol significantly reduced the total oxidant status (TOS) and oxidative stress index (OSI) in FF (P = 0.0142 and P = 0.0039, respectively) while increasing the total antioxidant capacity (TAC) (P < 0.0009). Resveratrol consumption also led to significant increases in the expression of critical genes involved in mitochondrial biogenesis, including peroxisome proliferator-activated receptor gamma coactivator (PGC-1α) and mitochondrial transcription factor A (TFAM) (P = 0.0032 and P = 0.0003, respectively). However, the effect on nuclear respiratory factor 1 (Nrf-1) expression was not statistically significant (P = 0.0611). Resveratrol significantly affected sirtuin1 (SIRT1) and PGC-1α protein levels (P < 0.0001 and P = 0.0036, respectively). Resveratrol treatment improved the mtDNA copy number (P < 0.0001) and ATP content in GCs (P = 0.0014). Clinically, the resveratrol group exhibited higher rates of oocyte maturity (P = 0.0012) and high-quality embryos (P = 0.0013) than did the placebo group. There were no significant differences between the groups in terms of chemical or clinical pregnancy rates (P > 0.05).
CONCLUSIONS: These findings indicate that resveratrol may be a promising therapeutic agent for patients with PCOS undergoing assisted reproduction.
BACKGROUND: http://www.irct.ir ; IRCT20221106056417N1; 2023 February 09.
METHODS: Fifty-six patients with PCOS were randomly assigned to receive 800 mg/day of resveratrol or placebo for 60 days. The primary outcome was OS in follicular fluid (FF). The secondary outcome involved assessing gene and protein expression related to mitochondrial biogenesis, mitochondrial DNA (mtDNA) copy number, and adenosine triphosphate (ATP) content in granulosa cells (GCs). ART outcomes were evaluated at the end of the trial.
RESULTS: Resveratrol significantly reduced the total oxidant status (TOS) and oxidative stress index (OSI) in FF (P = 0.0142 and P = 0.0039, respectively) while increasing the total antioxidant capacity (TAC) (P < 0.0009). Resveratrol consumption also led to significant increases in the expression of critical genes involved in mitochondrial biogenesis, including peroxisome proliferator-activated receptor gamma coactivator (PGC-1α) and mitochondrial transcription factor A (TFAM) (P = 0.0032 and P = 0.0003, respectively). However, the effect on nuclear respiratory factor 1 (Nrf-1) expression was not statistically significant (P = 0.0611). Resveratrol significantly affected sirtuin1 (SIRT1) and PGC-1α protein levels (P < 0.0001 and P = 0.0036, respectively). Resveratrol treatment improved the mtDNA copy number (P < 0.0001) and ATP content in GCs (P = 0.0014). Clinically, the resveratrol group exhibited higher rates of oocyte maturity (P = 0.0012) and high-quality embryos (P = 0.0013) than did the placebo group. There were no significant differences between the groups in terms of chemical or clinical pregnancy rates (P > 0.05).
CONCLUSIONS: These findings indicate that resveratrol may be a promising therapeutic agent for patients with PCOS undergoing assisted reproduction.
BACKGROUND: http://www.irct.ir ; IRCT20221106056417N1; 2023 February 09.
摘要：
背景：本研究旨在研究白藜芦醇对线粒体生物发生的影响，氧化应激（OS），多囊卵巢综合征（PCOS）患者的辅助生殖技术（ART）结局。
方法：56名PCOS患者被随机分配接受800毫克/天的白藜芦醇或安慰剂治疗60天。主要结果是卵泡液（FF）中的OS。次要结果涉及评估与线粒体生物发生相关的基因和蛋白质表达，线粒体DNA(mtDNA)拷贝数,颗粒细胞（GC）中的三磷酸腺苷（ATP）含量。在试验结束时评估ART结果。
结果：白藜芦醇可显著降低FF的总氧化状态（TOS）和氧化应激指数（OSI）（分别为P=0.0142和P=0.0039），同时增加总抗氧化能力（TAC）（P<0.0009）。白藜芦醇的消耗还导致线粒体生物发生中涉及的关键基因的表达显着增加，包括过氧化物酶体增殖物激活受体γ辅激活因子（PGC-1α）和线粒体转录因子A（TFAM）（分别为P=0.0032和P=0.0003）。然而,对核呼吸因子1(Nrf-1)表达的影响无统计学意义(P=0.0611)。白藜芦醇显着影响sirtuin1（SIRT1）和PGC-1α蛋白水平（分别为P<0.0001和P=0.0036）。白藜芦醇处理提高了GCs中mtDNA拷贝数(P<0.0001)和ATP含量(P=0.0014)。临床上,白藜芦醇组的卵母细胞成熟度(P=0.0012)和胚胎质量(P=0.0013)高于安慰剂组.两组间的化学妊娠率和临床妊娠率差异均无统计学意义(P>0.05)。
结论：这些研究结果表明，白藜芦醇可能是PCOS辅助生殖患者的一种有希望的治疗药物。
背景：http://www.irct.红外光谱；IRCT20221106056417N1；2023年2月09日。
方法：56名PCOS患者被随机分配接受800毫克/天的白藜芦醇或安慰剂治疗60天。主要结果是卵泡液（FF）中的OS。次要结果涉及评估与线粒体生物发生相关的基因和蛋白质表达，线粒体DNA(mtDNA)拷贝数,颗粒细胞（GC）中的三磷酸腺苷（ATP）含量。在试验结束时评估ART结果。
结果：白藜芦醇可显著降低FF的总氧化状态（TOS）和氧化应激指数（OSI）（分别为P=0.0142和P=0.0039），同时增加总抗氧化能力（TAC）（P<0.0009）。白藜芦醇的消耗还导致线粒体生物发生中涉及的关键基因的表达显着增加，包括过氧化物酶体增殖物激活受体γ辅激活因子（PGC-1α）和线粒体转录因子A（TFAM）（分别为P=0.0032和P=0.0003）。然而,对核呼吸因子1(Nrf-1)表达的影响无统计学意义(P=0.0611)。白藜芦醇显着影响sirtuin1（SIRT1）和PGC-1α蛋白水平（分别为P<0.0001和P=0.0036）。白藜芦醇处理提高了GCs中mtDNA拷贝数(P<0.0001)和ATP含量(P=0.0014)。临床上,白藜芦醇组的卵母细胞成熟度(P=0.0012)和胚胎质量(P=0.0013)高于安慰剂组.两组间的化学妊娠率和临床妊娠率差异均无统计学意义(P>0.05)。
结论：这些研究结果表明，白藜芦醇可能是PCOS辅助生殖患者的一种有希望的治疗药物。
背景：http://www.irct.红外光谱；IRCT20221106056417N1；2023年2月09日。
